Misuse of Drugs Act 1971

1 U.K. The following substances and products, namely:—

[F1 (a)]

• Acetyldihydrocodeine.

• Amphetamine.

• [F2 Cannabinol]

• [F2 Cannabinol derivatives]

• [F2 Cannabis and cannabis resin]

• F3 ...

• Codeine.

• F4 . . .

• Dihydrocodeine.

• Ethylmorphine (3-ethylmorphine).

• [F5 Glutethimide.]

• [F5 Lefetamine.]

• [F6 Mecloqualone.]

• [F6 Methaqualone.]

• [F7 Methcathinone]

• [F8 4–Methylmethcathinone]

• F9 ...

• [F10 a-Methylphenethylhydroxylamine]

• Methylphenidate.

• [F6 Methylphenobarbitone.]

• Nicocodine.

• [F11 Nicodicodine (6-nicotinoyldihydrocodeine).]

• Norcodeine.

• [F12 Pentazocine.]

• Phenmetrazine.

• Pholcodine.

• [F13 Propiram.]

• [F7 Zipeprol]

[F14 (aa) Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say,

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]

[F15 (ab) Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1-position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say,

(i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3–position with an alkyl substituent;

(iii) by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.]

[F1 (b) any 5,5 disubstituted barbituric acid.]

[F16 (c) [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.

3–Dimethylheptyl–11–hydroxyhexahydrocannabinol.

[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.

9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.

Nabilone.

• Any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• Any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• Any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

• Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

• Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.]

Textual Amendments

F1 Sch. 2 Pt. 2 para. 1(b) added by S.I. 1984/859, art. 2(3)

F2 Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(a)

F3 Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201), art. 2(3)

F4 Word repealed by S.I. 1985/1995, art. 2(2)(a)

F5 Word inserted by S.I. 1985/1995, art. 2(2)(b)

F6 Word inserted by S.I. 1984/859, art. 2(3)

F7 Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(3)

F8 Word in Sch. 2 Pt. 2 para. 1(a) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(a)

F9 Word in Sch. 2 Pt. 2 para. 1(a) repealed (18.1.2007) by The Misuse of Drugs Act 1971 (Amendment) Order 2006 (S.I.2006/3331), art. 2(2)

F10 Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by S.I. 2001/3932, art. 2(3)

F11 Words inserted by S.I. 1973/771, art. 2

F12 Word inserted by S.I. 1985/1995, art. 2(2)(c)

F13 Word inserted by S.I. 1973/771, art. 2

F14 Sch. 2 Pt. 2 para. 1(aa) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(b)

F15 Sch. 2 Pt. 2 para. 1(ab) inserted (23.7.2010) by The Misuse of Drugs Act 1971 (Amendment No. 2) Order 2010 (S.I. 2010/1833), art. 2

F16 Sch. 2 Pt. 2 para. 1(c) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(2)(a)